Whether the insulin resistance commonly observed in patients with inflammatory arthritis is a disease-specific feature and/or is limited to a disease phase (i.e., it occurs only during phases of high disease activity) is unknown. Fifty-three rheumatoid arthritis (RA) and 44 psoriatic arthritis (PsA) patients were recruited consecutively along with 194 controls matched for age, sex and body mass index for a case-control study. All underwent an oral glucose tolerance test, the results of which were analysed to derive the following indexes: homeostatic model of insulin resistance (HOMA-IR), insulin sensitivity index (ISI) and early insulin sensitivity index (EISI). These data were related to anthropometric, clinical and laboratory findings. Metabolic parameters of patients and controls were similar. Neither inflammatory markers nor disease activity scores were related to glucose metabolism for the generality of RA and PsA patients; however, by restricting the analysis to the subset of RA patients with residual disease activity, an association emerged between erythrocyte sedimentation rate, on the one hand, and fasting insulin (β=0.46, p=0.047) and HOMA-IR (β=0.44, p=0.02), on the other. Moreover, C-reactive protein (CRP) levels were associated with plasma glucose and insulin levels measured 120 min after the glucose load (β=0.91, p=0.0003 and β=0.77, p=0.0006, respectively); ISI and EISI were predicted by CRP (β=-0.79, p=0.0006; β=-0.80, p=0.0001, respectively). The same did not hold true for PsA patients. The association between systemic inflammation and insulin resistance indexes is a feature of RA with residual disease activity, not a universal feature of inflammatory arthritides.
n INTRODUCTION C omorbidities, including diabetes, have become a hot topic in the management of inflammatory arthritis (1) . In this regard, an association has been reported between inflammation and insulin resistance in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) (2, 3) . Since insulin resistance is one of the major drivers of cardiovascular diseases, which in turn are responsible for a significant morbidity and mortality burden among patients with inflammatory arthritis (4) , this proposed association may have important clinical implications. First and foremost, it would support the hypothesis that better disease control may extend its benefits on cardiovascular health. Indeed, both classical and biological disease modifying anti-rheumatic drugs (DMARDs) improve insulin sensitivity (5, 6) , confirming that activation of inflammatory pathways may impair insulin action. The mechanisms linking insulin resistance and inflammatory arthritis are debated, however, and very limited data on insulin Inflammatory markers predict insulin sensitivity in active rheumatoid arthritis but not in psoriatic arthritis Inflammation and insulin sensitivity ORIGINAL PAPER resistance dynamically investigated by an oral glucose tolerance test (OGTT) exist (7) . Moreover, there is a paucity of data comparing glucose metabolism in RA vs PsA (8) . With the present study, we aim to fill these gaps.
n MATERIALS AND METHODS
In the present case-control study, cases were consecutively recruited at an immune-rheumatology clinic of an academic hospital, between November 2014 and June 2015. Inclusion criteria were: age >18, diagnosis of either RA (according to ACR/Eular classification criteria 2010 (9)) or PsA (according to CASPAR criteria (10) ). Patients were excluded if previously diagnosed as diabetics. The study was conducted according to the principles of the Helsinki Declaration. The following data were collected:
• Demographic and clinical characteristics: age, sex, active anti-rheumatic treatment, steroid treatment, cumulative dose of steroids administered in the preceding 3 and 12 months, comorbidities. The Disease Activity Score (DAS28), the Clinical Disease Activity Index (CDAI) and the Simplified Disease Activity Index (SDAI) were used to assess disease activity in RA; patients affected by PsA were classified as achieving minimal disease activity when 5 of the 7 following criteria were met: tender joint count ≤1; swollen joint count ≤1; Psoriasis Activity and Severity Index ≤1 or body surface area ≤3%; patient pain visual analogue score (VAS) ≤15; patient global disease activity VAS ≤20; health assessment questionnaire ≤0.5; tender entheseal points ≤1 (11).
• Anthropometric data: weight (to the nearest 0.1 kg) and height (to the nearest cm) were measured with the patient wearing only light underwear; body mass index (BMI) was calculated according to the formula weight (kg)/height (m) 2 , and interpreted according to WHO classification (http://www. euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/bodymass-index-bmi). Waist circumference was measured halfway between the costal edge and the crista.
• Laboratory data: erythrocyte sedimentation rate (ESR) was measured by the Westergren method (VES-Matic Cube 200", DIESSE Diagnostica senese, Siena, Italy); C-Reactive Protein (CRP) was dosed by immunoturbidimetric analysis (Advia 1800 chemistry system, Siemens healthcare and diagnostics, Leverkusen, Germany). All patients underwent a standard OGTT: following at least 12 hours of fasting, 75 grams of glucose were administered after a first, baseline, blood sampling. A second sample was taken after 2 hours. Plasma glucose was measured by the hexokinase-reaction (Advia 1800 chemistry system, Siemens healthcare and diagnostics, Leverkusen, Germany), while insulin plasma concentration was determined by immunometric sandwich chemiluminescence (Advia Centaur, Siemens healthcare and diagnostics, Leverkusen, Germany). The results of the OGTT were interpreted according to ADA recommendations (12), as follows: normal fasting plasma glucose (FPG) if <100 mg/ dl (5.6 mmol/l); impaired FPG (IFG) if FPG was 100-125 mg/dl (6.9 mmol/l); impaired glucose tolerance (IGT) if 2-h post-OGTT plasma glucose was 140-199 mg/dl (7.8-11.0 mmol/l); T2DM if FPG was ≥126 mg/dl (≥7 mmol/l) on two days apart, or if 2-h post-OGTT plasma glucose (2hPG) was ≥200 mg/dl (≥11.1 mmol/l). Glycated haemoglobin (HbA1c) was simultaneously measured by a chromatographic assay (Variant Biorad, Hercules, California, USA). HbA1c values of 5.7 and 6.5% were considered as thresholds for normal glucose metabolism and T2DM, respectively. . The existence of an association between potential predictors of glucose metabolism and blood glucose parameters was investigated by univariate analysis; the corresponding putative predictors of glucose metabolism were then used to build multivariate models of prediction. The significance level chosen for each test was 0.05 (two-tails).
n RESULTS
The study population included 53 consecutive patients with RA, 44 with PsA and 194 controls matched for age, sex and BMI. Demographic features, metabolic and disease-related parameters are reported in Table I. We found no significant differences comparing metabolic parameters of patients and controls (see Table I for details). We then performed a univariate analysis on RA patients, to search for predictors (age, BMI, WC, ESR, CRP, daily prednisone dose, disease duration, disease activity, DAS28, CDAI, SDAI) of FPG, 2hPG, FPI, 2hPI, Hb1Ac alteration and of n DISCUSSION Growing evidence has related insulin resistance to inflammatory arthritis (2, 3); in this OGTT-based study we have investigated this association both in RA and PsA. Interestingly, we found that the correlation between inflammation and insulin sensitivity is limited to patients with active RA, whereas it is not demonstrable in PsA.
Looking at the indices of glucose metabolism in RA patients, BMI was the strongest predictor of insulin resistance, in agreement with the literature suggesting that obesity is the main determinant of glucose tolerance (16) . On the other hand, prednisone use was the only predictor of 2hPG, as expected considering the detrimental impact of prednisone on insulin sensitivity. In PsA, disease duration predicted higher insulin plasma concentration after OGTT; prednisone use was less relevant, its effect being more limited in PsA than in RA. Interestingly, we were not able to confirm previous studies which proved an altered insulin sensitivity in RA and PsA with respect to a control population (2, 17) ; recently, results consistent with ours have been reported in a population of patients affected by early RA, the insulin sensitivity of whom was not different from a control group (18 (19, 20) . Two reasons may exist to explain this apparent discrepancy. Firstly, the patients enrolled in these studies had a significantly longer follow-up than our cohort PsA patients; secondly, for the present study we excluded PsA patients with a defined diagnosis of T2DM. As a matter of fact, we did not investigate incidence and prevalence of T2DM in PsA at all, since our aim was to give a cross-sectional picture of the association between inflammation and insulin sensitivity. On the other hand, the reason(s) why inflammatory markers are less predictive of glucose metabolism impairment in PsA than in RA could be: i) the heterogeneity of PsA; and/or ii) the fact that in PsA inflammatory markers reflect disease activity less well, especially among patients whose disease is mainly characterized by enthesopathy manifestations. Due to these limitations, we cannot entirely dismiss the hypothesis that a larger sample and a more disease-specific stratification of activ- Our study has other limitations. As just mentioned, its nature is explorative, with a relatively small sample size and short follow-up; a larger population is required to confirm our results and to allow a more comprehensive analysis. Specifically, it would be interesting to evaluate the response to OGTT, grouping patients according to the type of anti-rheumatic treatment in use, since it has been shown that some of the classical and biological DMARDs commonly employed in clinical practice have a positive impact on insulin sensitivity (5, 6, 21) . On the other hand, we would like to point out that a novel aspect of the study is the comparison of glucose metabolism between RA and PsA. These two conditions are characterized by a very different biological behavior, which arguably is reflected on relevant differences in comorbidities.
n CONCLUSIONS
In conclusion, appropriate management of comorbidities demands that an altered glucose metabolism should be ruled out for all patients affected by inflammatory arthritis. However, to interpret correctly the results of metabolic studies, clinicians need to be aware that the impact of disease activity is not necessarily similar for all rheumatic diseases. Our data indicate that they should be particularly alerted to its influence on patients with RA, among whom not only fasting insulin sensitivity, but also the response to an oral glucose load bears a relationship with inflammatory markers. 
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